VC
APLS

Vivo Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Vivo Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-383,538
Closed -$9.72M – 8
2019
Q2 		$9.72M Hold
383,538
– – 0.91% 29
2019
Q1 		$7.48M Sell
383,538
-491,035
-56% -$7.72M 0.75% 34
2018
Q4 		$11.5M Sell
874,573
-479,981
-35% -$7.36M 1.47% 21
2018
Q3 		$24.1M Sell
1,354,554
-101,945
-7% -$1.88M 2.43% 14
2018
Q2 		$32M Sell
1,456,499
-1,335
-0.1% -$30.7K 4.13% 7
2018
Q1 		$32.2M Hold
1,457,834
– – 4.57% 5
2017
Q4 		$31.6M Buy
+1,457,834
New +$21.5M 6.78% 4

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Vivo Capital's APLS Position: Q3 2019 in Review

Vivo Capital sold out of Apellis Pharmaceuticals (APLS) in Q3 2019, closing a stake of 383,538 shares — an estimated $9.72M sold.

Vivo Capital first reported a position in APLS in Q4 2017 and held it in 7 quarters. The position peaked at $32.2M in Q1 2018. 129 funds tracked by Wall St. Rank hold APLS as of Q3 2019.

  • Vivo Capital reported no remaining Apellis Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Vivo Capital sold 383,538 Apellis Pharmaceuticals shares in Q3 2019, an estimated $9.72M.
  • Vivo Capital first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 7 quarters.
  • Vivo Capital's Apellis Pharmaceuticals position peaked at $32.2M in Q1 2018.
  • 129 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2019.

Based on Vivo Capital's 13F filing for Q3 2019, filed 13 Nov 2019.